

# Pharmaceutical Pipeline – Key Events in 2021\*

## Potential Approvals US/EU

amivantamab (EGFR/cMET)	– Non Small Cell Lung Cancer (US)
ciltacabtagene autoleucel (BCMA CAR-T)	– Multiple Myeloma (US)
DARZALEX® (daratumumab)	– Amyloidosis (ANDROMEDA) (US ✓ / EU ) – Relapsed Refractory Multiple Myeloma w/PomDex (US / EU )
XARELTO® (rivaroxaban)	– Infrainguinal revascular PAD (US) – Pediatric VTE (US)
SPRAVATO® (esketamine nasal spray)	– Major Depressive Disorder in a Psychiatric Emergency (EU ✓ )
paliperidone palmitate 6-month	– Schizophrenia (US )
PONVORY™ (ponesimod)	– Relapsing Forms of Multiple Sclerosis (US ✓ / EU )
CABENUVA® (rilpivrine long acting)	– HIV (US ✓ )
UPTRAVI® IV	– Pulmonary arterial hypertension (US)
VAC31518	– Janssen COVID-19 Vaccine (US EUA ✓ , EU cMAA ✓)

## Planned Submissions US/EU

ciltacabtagene autoleucel (BCMA CAR-T)	– Multiple Myeloma (US submission complete ✓ , EU )
amivantamab (EGFR/cMET)	– Non Small Cell Lung Cancer (EU ✓ )
IMBRUVICA® (ibrutinib)	– Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (US , EU )
XARELTO® (rivaroxaban)	– Pediatric VTE (US)
VAC31518	– Janssen COVID-19 Vaccine (US EUA ✓ , EU cMAA ✓)

## Potential Clinical Data Presentations

### Phase 3

STELARA® (ustekinumab)	– Crohn's Disease H2H vs. HUMIRA (SEAVUE)
paliperidone palmitate 6-month	– Schizophrenia (PSY3015)
IMBRUVICA® (ibrutinib)	– Frontline chronic lymphocytic leukemia (I+V fixed duration) (GLOW)
ERLEADA® (apalutamide)	– Metastatic castrate sensitive prostate cancer- Final Analysis (TITAN) ✓

### Phase 2

tesnatilamab (anti-NKG2D)	– Crohn's Disease (TRIDENT)
amivantamab (EGFR/cMET)	– 2L NSCLC (CHRYSALIS) ✓
milvexian (factor XIa)	– Total Knee Replacement (AXIOMATIC-TKR)
ciltacabtagene autoleucel (BCMA CAR-T)	– Multiple Myeloma (CARTITUDE-1 Longer term follow-up)

✓ = Achieved